Retrospective Analysis of Rituximab-containing Immunochemotherapy for Burkitt's or Burkitt-like Lymphoma in Adults
This retrospective study is aimed at evaluating the safety and efficacy of rituximab-containing immunochemotherapy in adult patients with Burkitt's lymphoma (BL) or high-grade B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and BL.
Burkitt's Lymphoma|High-grade B-cell Lymphoma
OTHER: No intervention (observational study)
Event-free survival, Event-free survival is measured from the time from treatment initiation to any treatment failure including disease progression, or discontinuation of treatment for any reason (eg, disease progression, toxicity, patient preference, initiation of new treatment without documented progression, or death), one year
complete response rate, treatment response will be evaluated according to the Revised criteria for malignant lymphoma (Journal of Clinical Oncology 25:579-586), 1-year|overall survival, Overall survival is defined as the time from treatment initiation until death as a result of any cause, 1-year|Grade 4 hematologic toxicities, toxicities will be graded according to Common Toxicity Criteria for Adverse Events (CTCAE) V.4.0. Hematologic toxicities planned to evaluated were; anemia (by hemoglobin), absolute neutrophil count, and platelet count, one year
Inclusion criteria

1. pathologically confirmed BL or BL-U by World Health Organization 2008 criteria
2. age \>20 yrs
3. received rituximab+chemotherapy as first-line treatment
4. with measurable or evaluable lesion
5. with complete set of clinical and laboratory data for the analysis